Landon Hughes, BA, PhD

Yerby Fellow, Harvard T.H. Chan School of Public Health

Postdoctoral Research Fellow, Department of Population Medicine at Harvard Medical School

Landon Hughes is currently a Yerby Fellow at the Harvard T.H. Chan School of Public Health and also holds a position as a Postdoctoral Research Fellow in the Department of Population Medicine at Harvard Medical School. Before joining Harvard, Landon completed a Ph.D. in Health Behavior and Health Education at the University of Michigan and a BA in Sociology and Political Science at Grand Valley State University.  As a social epidemiologist, his research utilizes demographic methods to examine morbidity and mortality among LGBTQ populations and considers the effects of social factors on health and aging. He works alongside Dr. Brittany Charlton to examine pre- and perinatal health and aging among LGBTQ populations.

 

Representative Publications:

  1. Hughes LD, King W, Gamarel K, Geronimus AT, Panagiotou O, Hughto JMW.S. Black-White Differences in Mortality Risk Among Transgender and Cisgender People in Private Insurance, 2011-2019. American Journal of Public Health 2022; 112 1507-1514.
  2. Hughes LD, Dowshen N, Kidd K, Operario D, Renjilian C, Gamarel K. Pediatric provider perspectives on laws and policies impacting sports participation for transgender youth. LGBT Health 2022; 9(4) 247-253.
  3. Hughes LD, King W, Gamarel K, Geronimus AT, Panagiotou O, Hughto JMW. Mortality differences among transgender and non-transgender people enrolled in private insurance (2011-2019). Demography 2022; 59(3) 1023–1043.
  4. Hughto JMW, Hughes LD, Yee K, Downing J, Ellison J, Alpert A, Jasuja GK, Shireman TI.  Improving data-driven methods to identify and categorize transgender individuals by gender in insurance claims data. LGBT Health 2022; 9(4) 254-263.
  5. Hughes LD, Kidd K, Gamarel KE, Operario D, Dowshen N. “These laws will be devastating”: provider perspectives on legislation banning gender-affirming care for transgender adolescents. Journal of Adolescent Health 2021; 69(6) 976-982.
  6. Hughes LD, Gamarel KE, King WM, Goldenberg T, Jaccard J, Geronimus AT. State-level policy stigma and non-prescribed hormones use among trans populations in the United States: a mediational analysis of insurance and anticipated stigma. Annals of Behavioral Medicine 2021; 55(10).
  7. Hughes LD, Shireman TI, Hughto J. Privately insured transgender people are at elevated risk for chronic conditions compared with cisgender counterparts. Health Affairs 2021; 40(9) 1440-1448.
  8. Hughes, LD, Berzin OK, Leung, MY, Hersey C, Grallert S. Adapting health care quality measures to transgender individuals. LGBT Health 2017;4(4) 167–178.